BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2013;11:333-342; quiz e30-e31. [PMID: 23142604 DOI: 10.1016/j.cgh.2012.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Pesce E, Gorrieri G, Sirci F, Napolitano F, Carrella D, Caci E, Tomati V, Zegarra-Moran O, di Bernardo D, Galietta LJ. Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel. J Cyst Fibros 2016;15:425-35. [PMID: 26971626 DOI: 10.1016/j.jcf.2016.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
2 Carrion A, Borowitz DS, Freedman SD, Siracusa CM, Goralski JL, Hadjiliadis D, Srinivasan S, Stokes DC. Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series. Journal of Pediatric Gastroenterology & Nutrition 2018;66:451-4. [DOI: 10.1097/mpg.0000000000001788] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
3 Faure C. Lubiprostone in Pediatric Functional Constipation. Journal of Pediatric Gastroenterology & Nutrition 2014;58:275-7. [DOI: 10.1097/mpg.0000000000000268] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Kondori N, Lindblad A, Welinder-Olsson C, Wennerås C, Gilljam M. Development of IgG antibodies to Exophiala dermatitidis is associated with inflammatory responses in patients with cystic fibrosis. J Cyst Fibros 2014;13:391-9. [PMID: 24439251 DOI: 10.1016/j.jcf.2013.12.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
5 Beaufils F, Mas E, Mittaine M, Addra M, Fayon M, Delhaes L, Clouzeau H, Galode F, Lamireau T, Bui S, Enaud R. Increased Fecal Calprotectin Is Associated with Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic Fibrosis. J Clin Med 2020;9:E4080. [PMID: 33348735 DOI: 10.3390/jcm9124080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mall MA, Galietta LJ. Targeting ion channels in cystic fibrosis. J Cyst Fibros 2015;14:561-70. [PMID: 26115565 DOI: 10.1016/j.jcf.2015.06.002] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 14.0] [Reference Citation Analysis]
7 Galante G, Freeman AJ. Gastrointestinal, Pancreatic, and Hepatic Manifestations of Cystic Fibrosis in the Newborn. Neoreviews 2019;20:e12-24. [PMID: 31261070 DOI: 10.1542/neo.20-1-e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Deane J, Fouhy F, Ronan NJ, Daly M, Fleming C, Eustace JA, Shanahan F, Flanagan ET, Dupont L, Harrison MJ, Haworth CS, Floto A, Rea MC, Ross RP, Stanton C, Plant BJ. A multicentre analysis of Clostridium difficile in persons with Cystic Fibrosis demonstrates that carriage may be transient and highly variable with respect to strain and level. J Infect 2021;82:363-70. [PMID: 33444699 DOI: 10.1016/j.jinf.2020.12.027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Munck A, Languepin J, Debray D, Lamireau T, Abely M, Huet F, Maudinas R, Michaud L, Mas E. Management of pancreatic, gastrointestinal and liver complications in adult cystic fibrosis. Revue des Maladies Respiratoires 2015;32:566-85. [DOI: 10.1016/j.rmr.2014.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
10 Cribbs SK, Beck JM. Microbiome in the pathogenesis of cystic fibrosis and lung transplant-related disease. Transl Res 2017;179:84-96. [PMID: 27559681 DOI: 10.1016/j.trsl.2016.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
11 Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190:175-184. [PMID: 24927234 DOI: 10.1164/rccm.201404-0703oc] [Cited by in Crossref: 299] [Cited by in F6Publishing: 148] [Article Influence: 37.4] [Reference Citation Analysis]
12 Spanò V, Barreca M, Cilibrasi V, Genovese M, Renda M, Montalbano A, Galietta LJV, Barraja P. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein. Molecules 2021;26:1275. [PMID: 33652850 DOI: 10.3390/molecules26051275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lara-Reyna S, Holbrook J, Jarosz-Griffiths HH, Peckham D, McDermott MF. Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cell Mol Life Sci 2020;77:4485-503. [PMID: 32367193 DOI: 10.1007/s00018-020-03540-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
14 Pope CE, Vo AT, Hayden HS, Weiss EJ, Durfey S, McNamara S, Ratjen A, Grogan B, Carter S, Nay L, Parsek MR, Singh PK, McKone EF, Aitken ML, Rosenfeld MR, Hoffman LR. Changes in fecal microbiota with CFTR modulator therapy: A pilot study. J Cyst Fibros 2021;20:742-6. [PMID: 33390317 DOI: 10.1016/j.jcf.2020.12.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 van Dorst JM, Tam RY, Ooi CY. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics? Nutrients 2022;14:480. [DOI: 10.3390/nu14030480] [Reference Citation Analysis]
16 Chin M, Aaron SD, Bell SC. The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Med 2017;46:e139-64. [PMID: 28576636 DOI: 10.1016/j.lpm.2016.11.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
17 Meurer SK, Alsamman M, Scholten D, Weiskirchen R. Endoglin in liver fibrogenesis: Bridging basic science and clinical practice. World J Biol Chem 2014; 5(2): 180-203 [PMID: 24921008 DOI: 10.4331/wjbc.v5.i2.180] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
18 Drzymała-Czyż S, Krzyżanowska P, Koletzko B, Nowak J, Miśkiewicz-Chotnicka A, Moczko JA, Lisowska A, Walkowiak J. Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis. Int J Mol Sci 2017;18:E185. [PMID: 28106773 DOI: 10.3390/ijms18010185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Matson AG, Bunting JP, Kaul A, Smith DJ, Stonestreet J, Herd K, Hodgson RS, Bell SC. A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. BMC Gastroenterol 2019;19:89. [PMID: 31195989 DOI: 10.1186/s12876-019-0979-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
20 Dos Santos ALM, de Melo Santos H, Nogueira MB, Távora HTO, de Lourdes Jaborandy Paim da Cunha M, de Melo Seixas RBP, de Freitas Velloso Monte L, de Carvalho E. Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents. Pediatr Gastroenterol Hepatol Nutr 2018;21:306-14. [PMID: 30345244 DOI: 10.5223/pghn.2018.21.4.306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
21 Ye W, Narkewicz MR, Leung DH, Karnsakul W, Murray KF, Alonso EM, Magee JC, Schwarzenberg SJ, Weymann A, Molleston JP; CFLDnet research group. Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis. J Pediatr Gastroenterol Nutr 2018;66:122-7. [PMID: 28906321 DOI: 10.1097/MPG.0000000000001728] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
22 Piccolo F, Tai AS, Ee H, Mulrennan S, Bell S, Ryan G. Clostridium difficile infection in cystic fibrosis: an uncommon but life-threatening complication. Respirol Case Rep 2017;5:e00204. [PMID: 28078087 DOI: 10.1002/rcr2.204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Schroeder I, Dichtl K, Liebchen U, Wagener J, Irlbeck M, Zoller M, Scharf C. Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients. Infection 2021;49:241-8. [PMID: 32880845 DOI: 10.1007/s15010-020-01506-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS. Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med 2015;36:299-320. [PMID: 25826595 DOI: 10.1055/s-0035-1547347] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
25 Nowak JK, Grulkowski I, Karnowski K, Wojtkowski M, Walkowiak J. Optical coherence tomography identifies lower labial salivary gland surface density in cystic fibrosis. PLoS One 2015;10:e0117517. [PMID: 25622042 DOI: 10.1371/journal.pone.0117517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
26 Sathe MN, Freeman AJ. Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis. Pediatr Clin North Am 2016;63:679-98. [PMID: 27469182 DOI: 10.1016/j.pcl.2016.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
27 Amato F, Scudieri P, Musante I, Tomati V, Caci E, Comegna M, Maietta S, Manzoni F, Di Lullo AM, De Wachter E, Vanderhelst E, Terlizzi V, Braggion C, Castaldo G, Galietta LJV. Two CFTR mutations within codon 970 differently impact on the chloride channel functionality. Hum Mutat 2019;40:742-8. [PMID: 30851139 DOI: 10.1002/humu.23741] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
28 Haller W, Ledder O, Lewindon PJ, Couper R, Gaskin KJ, Oliver M. Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications: Gastrointestinal disease in cystic fibrosis. J Gastroenterol Hepatol 2014;29:1344-55. [DOI: 10.1111/jgh.12546] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Bolia R, Ooi CY, Lewindon P, Bishop J, Ranganathan S, Harrison J, Ford K, van der Haak N, Oliver MR. Practical approach to the gastrointestinal manifestations of cystic fibrosis. J Paediatr Child Health 2018;54:609-19. [PMID: 29768684 DOI: 10.1111/jpc.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla CM, Matthys C, Miljuš G, Mooij MG, Parrott N, Ungell A, de Wildt SN, Orlu M, Klein S, Müllertz A. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. European Journal of Pharmaceutical Sciences 2020;147:105280. [DOI: 10.1016/j.ejps.2020.105280] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
31 van de Peppel IP, Doktorova M, Berkers G, de Jonge HR, Houwen RHJ, Verkade HJ, Jonker JW, Bodewes FAJA. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. J Cyst Fibros 2019;18:286-93. [PMID: 30279125 DOI: 10.1016/j.jcf.2018.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
32 Karb DB, Cummings LC. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:17. [PMID: 34448955 DOI: 10.1007/s11894-021-00817-2] [Reference Citation Analysis]
33 Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci 2014;15:13529-49. [PMID: 25093717 DOI: 10.3390/ijms150813529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
34 Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene. 2016;35:4179-4187. [PMID: 26751771 DOI: 10.1038/onc.2015.483] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
35 Tu Z, Chen Q, Zhang JT, Jiang X, Xia Y, Chan HC. CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis. Oncotarget. 2016;7:76955-76965. [PMID: 27769067 DOI: 10.18632/oncotarget.12762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
36 Ratchford TL, Teckman JH, Patel DR. Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Review of Gastroenterology & Hepatology 2018;12:853-62. [DOI: 10.1080/17474124.2018.1502663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
37 Middour-Oxler B, Gettis M, Dye B. Decreased Wait Time and Increased Satisfaction With Bedside Pancreatic Enzyme Dosing for the Inpatient Adolescent With Cystic Fibrosis: A Quality Improvement Project Comparing Enzyme Self-Administration to Nurse Administration. J Patient Exp 2021;8:2374373520981490. [PMID: 34179359 DOI: 10.1177/2374373520981490] [Reference Citation Analysis]
38 Fraquelli M, Baccarin A, Corti F, Conti CB, Russo MC, Valle SD, Pozzi R, Cressoni M, Conte D, Colombo C. Bowel ultrasound imaging in patients with cystic fibrosis: Relationship with clinical symptoms and CFTR genotype. Digestive and Liver Disease 2016;48:271-6. [DOI: 10.1016/j.dld.2015.09.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
39 Ingravalle F, Casella G, Ingravalle A, Monti C, De Salvatore F, Stillitano D, Villanacci V. Surveillance of Colorectal Cancer (CRC) in Cystic Fibrosis (CF) Patients. GastrointestDisord 2021;3:84-95. [DOI: 10.3390/gidisord3020009] [Reference Citation Analysis]
40 Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 2013;19:676-80. [PMID: 24060981 DOI: 10.1097/MCP.0b013e3283659ef2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
41 Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, Karp PH, Samuel MS, Reznikov LR, Rector MV, Gansemer ND, Bouzek DC, Abou Alaiwa MH, Hoegger MJ, Ludwig PS, Taft PJ, Wallen TJ, Wohlford-Lenane C, McMenimen JD, Chen JH, Bogan KL, Adam RJ, Hornick EE, Nelson GA 4th, Hoffman EA, Chang EH, Zabner J, McCray PB Jr, Prather RS, Meyerholz DK, Welsh MJ. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J Clin Invest 2013;123:2685-93. [PMID: 23676501 DOI: 10.1172/JCI68867] [Cited by in Crossref: 96] [Cited by in F6Publishing: 62] [Article Influence: 10.7] [Reference Citation Analysis]
42 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis 2017;16:S50-61. [DOI: 10.1016/j.jcf.2017.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
43 Huang YJ, LiPuma JJ. The Microbiome in Cystic Fibrosis. Clin Chest Med 2016;37:59-67. [PMID: 26857768 DOI: 10.1016/j.ccm.2015.10.003] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 12.0] [Reference Citation Analysis]
44 Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. Pharmacol Ther 2017;170:205-11. [PMID: 27916649 DOI: 10.1016/j.pharmthera.2016.11.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
45 Kessler L, Abély M. Atteinte pancréatique exocrine et endocrine dans la mucoviscidose. Archives de Pédiatrie 2016;23:12S21-32. [DOI: 10.1016/s0929-693x(17)30059-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Harutyunyan M, Huang Y, Mun KS, Yang F, Arora K, Naren AP. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Am J Physiol Lung Cell Mol Physiol 2018;314:L529-43. [PMID: 29351449 DOI: 10.1152/ajplung.00465.2017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
47 Culhane S, George C, Pearo B, Spoede E. Malnutrition in Cystic Fibrosis: A Review. Nutr Clin Pract 2013;28:676-83. [DOI: 10.1177/0884533613507086] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]